StataDx
Stata DX develops affordable eRapid tech for custom biomarker panels, enabling real-time, at-home patient monitoring in clinical studies.
Founded
2022Stata DX develops affordable eRapid tech for custom biomarker panels, enabling real-time, at-home patient monitoring in clinical studies.
StataDx, founded to revolutionize disease management, focuses on developing affordable eRapid technology for custom biomarker panels. Their core mission is to enable real-time, at-home patient monitoring in clinical studies, particularly for neurological conditions. The company offers a low-cost, affinity-based electrochemical sensing platform that can detect a wide range of biomarkers from a single drop of blood with high sensitivity and selectivity. StataDx aims to create a "liquid MRI" for the brain, facilitating multi-biomarker guided disease management strategies both in clinics and at home.
Notable affiliated individuals and investors include leading experts in neurology and biotechnology, though specific names are not provided. Key achievements include the development of multiplexed cartridges capable of supporting immunoassays, enzymatic assays, and nucleic acid detection, all connected via mobile and cloud platforms. StataDx's impact lies in its innovative approach to patient care, offering a modern, wire-free solution that replaces outdated point-of-care systems, significantly enhancing disease monitoring and management.
Companies similar to StataDx include StrokeDx, Mensura Health, Proactive Diagnostics and Starling.
StataDx was founded in 2022.
StataDx's headquarters is located in Cambridge, MA, US.
StataDx's most recent funding round was for $2.7M (USD) in February 2022.
As of Feb 7, 2022, StataDx has disclosed funding of $2.7M (USD). Undisclosed round amounts are excluded.
StataDx has 9 employees as of Feb 5, 2024.
Starling
